Bolt Biotherapeutics (BOLT) to Release Quarterly Earnings on Thursday

Bolt Biotherapeutics (NASDAQ:BOLT) is projected to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Bolt Biotherapeutics to post earnings of ($0.38) per share and revenue of $0.79 million for the quarter.

Bolt Biotherapeutics Stock Down 0.8 %

BOLT opened at $0.41 on Wednesday. The firm has a 50-day simple moving average of $0.48 and a two-hundred day simple moving average of $0.56. Bolt Biotherapeutics has a 52 week low of $0.39 and a 52 week high of $1.56. The company has a market capitalization of $15.58 million, a PE ratio of -0.24 and a beta of 0.94. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.